TopoTarget’s Dexrazoxane Approved In EU, “Approvable” In U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Company may seek partner to market drug in the U.S. after addressing manufacturing issues.
You may also be interested in...
Thelin Gets EMEA Committee Approval Recommendation
The European Medicines Agency's Committee for Medicinal Products for Human Use recommended marketing authorization approval of Encysive's pulmonary arterial hypertension therapy Thelin (sitaxsentan), the agency announced June 2
Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.
Lilly To Settle Additional Zyprexa Liability Cases, Will Pay Up To $500 Million
Lilly will pay up to $500 million to settle the "vast majority" of claims alleging that the company failed to adequately warn patients of risks associated with the atypical antipsychotic Zyprexa (olanzapine), the firm announced Jan. 4